Tuberculosis Diagnostics Market Report by Disease Stage, Test Type, End-User, and Region 2024-2032
세계의 결핵 진단 시장 규모는 2023년에 25억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 37억 달러에 달하며, 2024-2032년 4.2%의 성장률(CAGR)을 보일 것으로 예측하고 있습니다.
결핵은 주로 폐를 침범하고(폐 감염), 다른 부위(폐외 감염)를 침범하는 세균성 감염입니다. 결핵은 만토우-투베르쿨린 피부반응검사(TST) 또는 결핵 혈액검사를 통해 진단할 수 있습니다. 결핵의 확정 진단을 위해서는 감염된 장기에 따라 추가 검사가 필요합니다. 폐결핵의 경우 흉부 엑스레이 검사로 흉부 이상을 발견하고 가래의 산균 염색과 현미경 검사를 시행합니다. 폐외 결핵은 CT, MRI, 초음파 검사, 내시경 검사, 복강경 검사, 소변 검사, 혈액 검사, 생검, 요추 천자 등으로 진단할 수 있습니다.
결핵 진단 시장 동향 :
전 세계에서 다제내성(MDR) 결핵의 유병률이 증가하고 있는 것은 결핵에 대한 가장 강력한 항균제 중 하나로 여겨지는 이소니아지드와 리팜피신에 내성을 가진 박테리아에 의해 발생하는 MDR 결핵이 시장 성장을 가속하는 중요한 요인 중 하나입니다. 또한 기술적으로 진보된 POC(Point-of-Care) 진단법이 가능해졌습니다는 점도 시장 성장을 촉진하고 있습니다. 핵산 증폭 검사(NAAT)나 인터페론-감마 방출 분석(IGRA)과 같은 첨단 진단법은 기존에 사용되던 방법에 비해 더 정확하고 편리하며 빠른 결과를 얻을 수 있습니다. 또한 의료 인프라가 크게 개선되고 다양한 진단 방법에 대한 대중의 인식이 높아진 것도 또 다른 성장 촉진요인으로 작용하고 있습니다. 고령 인구 증가, 의료비 증가, 연구개발(R&D) 활동을 촉진하기 위한 정부의 구상과 투자 등이 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다룬 주요 질문
- 세계 결핵 진단 시장은 지금까지 어떻게 성장했으며, 앞으로 어떻게 성장하는가?
- 주요 지역 시장은 어디인가?
- COVID-19가 전 세계 결핵 진단 시장에 미친 영향은?
- 질병 단계에 따른 시장 분석은 무엇인가?
- 검사 유형에 따른 시장 분석은 무엇인가?
- 산업 밸류체인의 다양한 단계는?
- 업계의 주요 촉진요인과 과제는?
- 세계 결핵 진단 시장의 구조와 주요 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 개요
제4장 서론
제5장 세계의 결핵 진단 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 병기별
제7장 시장 내역 : 검사 유형별
- 방사선 검사
- 실험실 검사
- 핵산 검사
- 사이토카인 검출 검사
- 약제 내성 검사
- 기타
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁의 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 가격 지표
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업의 개요
- Abbott Laboratories
- Alere Inc.
- Becton Dickinson and Company
- BioMerieux
- Cepheid Inc.
- Epistem Ltd.
- Roche Holding AG
- Hain Lifescience GmbH
- Hologic Inc.
- QIAGEN GmbH
- Siemens
- Thermo Fisher Scientific Inc.
KSA
The global tuberculosis diagnostics market size reached US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032.
Tuberculosis (TB) refers to an infectious bacterial disease that primarily affects the lungs (pulmonary), along with other parts of the body (extrapulmonary). The infection is diagnosed via a Mantoux tuberculin skin test (TST) or the TB blood test. Additional tests are required to confirm TB disease, depending on the infected organs. In the case of pulmonary TB, chest radiography is performed for detecting chest abnormalities, along with acid-fast staining and microscopic examination of the patient's sputum. Extrapulmonary TB can be diagnosed using CT, MRI or ultrasound scans, endoscopy, laparoscopy, urine and blood tests, biopsies, and lumbar punctures.
Tuberculosis Diagnostics Market Trends:
The increasing prevalence of multi-drug resistant (MDR) tuberculosis across the globe is one of the key factors driving the growth of the market. MDR tuberculosis is caused by bacteria that are resistant to isoniazid and rifampicin, which are considered to be among the most potent antimicrobial drugs for TB. Furthermore, the availability of technologically advanced Point-of-Care (POC) diagnostic methods is also providing a boost to the market growth. Advanced diagnostic methods, such as Nucleic acid amplification tests (NAATs) and Interferon-Gamma Release Assay (IGRA), are more accurate, convenient, and provide prompt results in comparison to the traditionally used techniques. Additionally, significant improvements in the healthcare infrastructure, along with the growing awareness among the masses about various diagnostic procedures, are acting as another growth-inducing factor. Other factors, including the rising geriatric population and increasing healthcare expenditure and government initiatives and investments to promote research and development (R&D) activities, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global tuberculosis diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on disease stage, test type, and end-user.
Breakup by Disease Stage:
Latent TB
Active TB
Breakup by Test Type:
Radiographic Test
Laboratory Test
Smear Microscopy
Culture-based Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Others
Breakup by End-User:
Hospitals and Clinics
Diagnostics and Research Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Alere Inc., Becton Dickinson and Company, BioMerieux, Cepheid Inc., Epistem Ltd., Roche Holding AG, Hain Lifescience GmbH, Hologic Inc., QIAGEN GmbH, Siemens, Thermo Fisher Scientific Inc., etc.
Key Questions Answered in This Report:
- How has the global tuberculosis diagnostics market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global tuberculosis diagnostics market?
- What is the breakup of the market based on the disease stage?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global tuberculosis diagnostics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Tuberculosis Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Disease Stage
- 6.1 Latent TB
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Active TB
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Test Type
- 7.1 Radiographic Test
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Laboratory Test
- 7.2.1 Market Trends
- 7.2.2 Major Types
- 7.2.2.1 Smear Microscopy
- 7.2.2.2 Culture-based Test
- 7.2.3 Market Forecast
- 7.3 Nucleic Acid Testing
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Cytokine Detection Test
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Drug Resistance Test
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by End-User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostics and Research Laboratories
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Indicators
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Alere Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Becton Dickinson and Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 BioMerieux
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Cepheid Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 SWOT Analysis
- 14.3.6 Epistem Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Roche Holding AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Hain Lifescience GmbH
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.9 Hologic Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 QIAGEN GmbH
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.11 Siemens
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Thermo Fisher Scientific Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
